Pharnext S.C.A Past Earnings Performance

Past criteria checks 0/6

Pharnext S.C.A has been growing earnings at an average annual rate of 3.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 97.7% per year.

Key information

3.3%

Earnings growth rate

n/a

EPS growth rate

Biotechs Industry Growth30.8%
Revenue growth rate-97.7%
Return on equityn/a
Net Margin-16,004.3%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Pharnext's (EPA:ALPHA) Stock Price Has Reduced 66% In The Past Three Years

Feb 01
Pharnext's (EPA:ALPHA) Stock Price Has Reduced 66% In The Past Three Years

We Might See A Profit From Pharnext SA (EPA:ALPHA) Soon

Dec 09
We Might See A Profit From Pharnext SA (EPA:ALPHA) Soon

Revenue & Expenses Breakdown

How Pharnext S.C.A makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ENXTPA:ALPHA Revenue, expenses and earnings (EUR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 230-2840
30 Sep 234-2550
30 Jun 232-32820
31 Mar 232-35920
31 Dec 227-2870
30 Sep 225-32710
30 Jun 223-36720
31 Mar 223-33720
31 Dec 214-31720
30 Sep 214-28719
30 Jun 214-26818
31 Mar 213-24816
31 Dec 203-22814
30 Sep 203-21813
30 Jun 203-20813
31 Mar 203-22814
31 Dec 194-23815
30 Sep 194-24816
30 Jun 194-25817
31 Mar 195-23817
31 Dec 187-21718
30 Sep 187-20717
30 Jun 187-18617
31 Mar 185-19616
31 Dec 173-20616
30 Sep 173-20616
30 Jun 174-20516
31 Mar 174-19515
31 Dec 164-17414
30 Sep 164-16412
30 Jun 163-14410
31 Mar 163-1249
31 Dec 153-1148
31 Dec 143-1147

Quality Earnings: ALPHA is currently unprofitable.

Growing Profit Margin: ALPHA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if ALPHA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare ALPHA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALPHA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).


Return on Equity

High ROE: ALPHA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/05 05:37
End of Day Share Price 2025/01/03 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pharnext S.C.A. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Soo RomanoffEdison Investment Research
Damien ChoplainKepler Cheuvreux